

09/787995 **PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
Banellec, Didier et al

Examiner:

JCGS Rec'd PTO/CFC 23 MAR 2001  
Art Unit:

Serial No.: **NOT YET ASSIGNED**

Filed: **HEREWITH**

Title: **Use of Specific Hybrid Promoters  
For Controlling Tissue Expression**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

3/23/2001

Date of Deposit

*Helen Payne*

Signature

**EL 816576000 US**

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same and does not go beyond the disclosure in the international application as filed.

Respectfully submitted,

*Helen Payne*  
T. Helen Payne, Reg. No. 36,889  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-5789  
Telefax (908) 231-2626

Docket No. ST98032

09/787995

100

23 MAR 2001

ST98032.ST25  
SEQUENCE LISTING

<110> Aventis Pharma S.A.

<120> Use Of Specific Hybrid Promoters For Controlling Tissue Expression

<130> ST98032

<150> US 60/123298

<151> 1999-04-04

<150> FR/98/12000

<151> 1998-09-25

<160> 10

<170> PatentIn version 3.0

<210> 1

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(23)

<400> 1

gatggccct acttatgctg cta

23

<210> 2

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(23)

<400> 2

cttccatcat accaaactac ata

23

<210> 3

ST98032.ST25

<211> 32  
<212> DNA  
<213> Artificial sequence  
  
<220>  
<221> oligonucleotide  
<222> (1)..(32)  
  
<400> 3  
ctgctaaatt gctcgaggac aaatttagaca aa  
32  
  
<210> 4  
<211> 33  
<212> DNA  
<213> Artificial sequence  
  
<220>  
<221> oligonucleotide  
<222> (1)..(33)  
  
<400> 4  
ccctgacaaa gcttggctgg gctgctccac tgg  
33  
  
<210> 5  
<211> 30  
<212> DNA  
<213> Artificial sequence  
  
<220>  
<221> oligonucleotide  
<222> (1)..(30)  
  
<400> 5  
atcgacgcgt gcccgttaca taacttacgg  
30  
  
<210> 6  
<211> 38  
<212> DNA  
<213> Artificial sequence  
  
<220>  
<221> oligonucleotide

ST98032.ST25

<222> (1)..(38)

<400> 6  
atcgacgcgt ccgcgcgac gtcaatgggg cgagatgg  
38

<210> 7  
<211> 36  
<212> DNA  
<213> Artificial sequence

<220>  
<221> oligonucleotide  
<222> (1)..(36)

<400> 7  
ccaggtgtca ctcgagacta gttccacca actcga  
36

<210> 8  
<211> 36  
<212> DNA  
<213> Artificial sequence

<220>  
<221> oligonucleotide  
<222> (1)..(36)

<400> 8  
tcgttgaag cttgaaagg gatgttttc ggtgtc  
36

<210> 9  
<211> 30  
<212> DNA  
<213> Artificial sequence

<220>  
<221> oligonucleotide  
<222> (1)..(30)

<400> 9  
cccggtacat aacttacggt aaatggcccg  
30

ST98032.ST25

<210> 10  
<211> 30  
<212> DNA  
<213> Artificial sequence  
  
<220>  
<221> oligonucleotide  
<222> (1)..(30)  
  
<400> 10  
gggacgcgct tctacaaggc gctggccgaa  
30